Karsinoma Endometrium pada Seorang Pasien dengan Diabetes Mellitus Tipe 2: Laporan Kasus
Laporan Kasus
DOI:
https://doi.org/10.55175/cdk.v53i05.1007Kata Kunci:
Laporan kasus, diabetes melitus, kanker endometrium, hiperinsulinemia, obesitasAbstrak
Pendahuluan: Kanker endometrium sering dikaitkan dengan obesitas, diabetes melitus (DM) tipe 2, resistensi insulin, dan hiperinsulinemia. Kasus: Wanita berusia 71 tahun dengan riwayat DM tipe 2, hipertensi, dan obesitas (indeks massa tubuh/IMT 32,08 kg/m²) datang dengan keluhan nyeri perut hilang timbul dan perdarahan per vaginam. Pasien telah menjalani kuretase 2 minggu sebelumnya. Pemeriksaan USG menunjukkan massa hyperechoic di corpus uteri, dan hasil histopatologi pasca-laparatomi staging mengonfirmasi karsinoma endometrium tipe 2 (high-grade serous carcinoma) dengan metastasis ke omentum. Diagnosis karsinoma endometrium stadium IVB. Selama perawatan, pasien mendapat ceftriaxone secara intravena, insulin glargine, serta antihipertensi oral (ramipril dan nifedipine) Tata laksana utama direncanakan berupa kemoterapi sistemik dengan kombinasi carboplatin dan paclitaxel. Pembahasan: Diabetes melitus, terutama dengan hiperglikemia kronis, resistensi insulin, dan hiperinsulinemia, dikaitkan dengan peningkatan risiko berbagai kanker termasuk kanker endometrium, serta prognosis yang lebih buruk. Faktor seperti obesitas, usia, paparan estrogen, dan terapi insulin dapat memperkuat risiko ini, sementara biomarker seperti IGF-2 dan IGFBP-3 berpotensi digunakan untuk deteksi dini dan penilaian risiko kanker endometrium. Simpulan: Kasus ini menyoroti hubungan erat antara DM tipe 2, obesitas, dan kanker endometrium agresif, serta pentingnya deteksi dini dan penatalaksanaan komprehensif pada pasien dengan risiko metabolik.
Unduhan
Referensi
Lortet-Tieulent J, Ferlay J, Dos-Santos-Silva I, Brinton LA, Negri E, Peeters PH, et al. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2017;110(4):354–61. doi: 10.1093/jnci/djx214.
Saed L, Varsi F, Aziziaram Z, Baradaran B, McDonagh M, Gheshlagh RG, et al. The effect of diabetes on the risk of endometrial cancer: an updated systematic review and meta-analysis. BMC Cancer. 2019;19(1):527. doi: 10.1186/s12885-019-5748-4.
Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16(2):276–80. doi: 10.1158/1055-9965.EPI-06-0763.
Luo J, Chlebowski R, Hendryx M, Rohan T, Wactawski-Wende J, Thomson CA, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014;111(7):1432–9. doi: 10.1038/bjc.2014.407.
Anderson KE, Anderson E, Mink PJ, Hong CP, Sellers TA, Lazovich D, et al. Diabetes and endometrial cancer in the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev. 2001;10(6):611–6.
Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol. 2011;22(4):884–9. doi: 10.1093/annonc/mdq464.
Koskas M, Amant F, Mirza MR, Creutzberg CL. Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):45–60. doi: 10.1002/ijgo.13866.
PB Perkeni. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2021. Jakarta: PB Perkeni; 2021.
Ramadhan N, Marissa N, Fitria E, Wilya V. Pengendalian diabetes melitus tipe 2 pada pasien di Puskesmas Jayabaru Kota Banda Aceh. Media Litbangkes. 2018;28(4):239–46. doi: 10.22435/mpk.v28i4.108.
Liao C, Zhang D, Mungo C, Tompkins DA, Zeidan AM. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? a systematic review and meta-analysis of cohort studies. Gynecol Oncol. 2014;135(1):163–71. doi: 10.1016/j.ygyno.2014.07.095.
Joung KH, Jeong JW, Ku BJ. The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. BioMed Res Int. 2015;2015:920618. doi: 10.1155/2015/920618.
Liang YJ, Hao Q, Zhang H, Wu YZ, Wang JD. Insulin-like growth factors in endometrioid adenocarcinoma: correlation with clinico-pathological features and estrogen receptor expression. BMC Cancer. 2012;12:262. doi: 10.1186/1471-2407-12-262.
Oh JC, Wu W, Tortolero-Luna G, Broaddus RR, Gershenson DM, Burke TW, et al. Increased plasma levels of insulin-like growth factor-2 and insulin-like growth factor binding protein-3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13(5):748–52.
Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer. 1997;71(3):360–3. doi: 10.1002/(sici)1097-0215(19970502)71:3<360::aid-ijc10>3.0.co;2-v.
Habib SL, Rojna M. Diabetes and risk of cancer. ISRN Oncol. 2013;2013:583786. doi: 10.1155/2013/583786.
Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52(9):1745–54. doi: 10.1007/s00125-009-1444-2.
Janghorbani M, Dehghani M, Salehi-Marzijarani M. Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer. 2012;3(4):137–46. doi: 10.1007/s12672-012-0112-z.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2026 IDA BAGUS ADITYA NUGRAHA, WIRA GOTERA, DIAN DANIELLA, Thomas Aquinas Ehe Teron

Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.






